Fulcrum Therapeutics, Inc.
US ˙ NasdaqGM ˙ US3596161097

SecurityFULC / Fulcrum Therapeutics, Inc.
InstitutionMan Group plc
Latest Disclosed Ownership46,119 shares
Latest Disclosed Value $ 353,733
Man Group plc reports 202.36% increase in ownership of FULC / Fulcrum Therapeutics, Inc.

On May 15, 2026 - Man Group plc filed a 13F-HR form disclosing ownership of 46,119 shares of Fulcrum Therapeutics, Inc. (US:FULC) valued at $353,733 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 15,253 shares of Fulcrum Therapeutics, Inc.. This represents a change in shares of 202.36% during the quarter. The current value of the position is $148,503 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F FULCRUM THERAPEUTICS COM 359616109 46,119 30,866 202.36 354 105.23 0.0006
2026-02-17 2025-12-31 13F FULCRUM THERAPEUTICS COM 359616109 15,253 15,253 173 0.0003
2025-02-14 2024-12-31 13F FULCRUM THERAPEUTICS COM 359616109 0 -48,324 -100.00 0 -100.00
2024-11-14 2024-09-30 13F FULCRUM THERAPEUTICS COM 359616109 48,324 48,324 173 0.0004
2024-08-14 2024-06-30 13F FULCRUM THERAPEUTICS COM 359616109 0 -102,226 -100.00 0 -100.00
2024-05-15 2024-03-31 13F FULCRUM THERAPEUTICS COM 359616109 102,226 7,609 8.04 965 51.25 0.0024
2024-02-14 2023-12-31 13F FULCRUM THERAPEUTICS COM 359616109 94,617 94,617 639 0.0018
2023-05-15 2023-03-31 13F FULCRUM THERAPEUTICS COM 359616109 0 -96,152 -100.00 0 -100.00
2023-02-14 2022-12-31 13F FULCRUM THERAPEUTICS COM 359616109 96,152 10,394 12.12 700 0.72 0.0025
2022-11-14 2022-09-30 13F FULCRUM THERAPEUTICS COM 359616109 85,758 694 13.40 0.0032
2022-08-15 2022-06-30 13F FULCRUM THERAPEUTICS COM 359616109 612 0.0026
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.